These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 23833016)
1. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016 [TBL] [Abstract][Full Text] [Related]
2. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584 [TBL] [Abstract][Full Text] [Related]
3. Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. Wu J; Huang H Drug Des Devel Ther; 2020; 14():3977-3982. PubMed ID: 33061302 [TBL] [Abstract][Full Text] [Related]
4. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma. Koc G; Wang X; Luo Y Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325 [TBL] [Abstract][Full Text] [Related]
5. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550 [TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
7. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Hagiwara M; Borker R; Oster G Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735 [TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Oudard S; Elaidi RT Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686 [TBL] [Abstract][Full Text] [Related]
9. Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. Nearchou A; Valachis A; Lind P; Akre O; Sandström P Clin Genitourin Cancer; 2015 Aug; 13(4):280-286. PubMed ID: 25442773 [TBL] [Abstract][Full Text] [Related]
10. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284 [TBL] [Abstract][Full Text] [Related]
11. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Ainsworth NL; Lee JS; Eisen T Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for renal cell cancer: current perspectives. van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471 [TBL] [Abstract][Full Text] [Related]
13. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453 [TBL] [Abstract][Full Text] [Related]
14. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105 [TBL] [Abstract][Full Text] [Related]
15. Pazopanib for the treatment of metastatic renal cell carcinoma. Pick AM; Nystrom KK Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 induces drug resistance in renal cell carcinoma. Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518 [TBL] [Abstract][Full Text] [Related]
17. Recent advances and future directions in the management of metastatic renal cell carcinoma. Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547 [TBL] [Abstract][Full Text] [Related]
18. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma. Srinivas S; Stein D; Teltsch DY; Tao S; Cisar L; Ramaswamy K J Oncol Pharm Pract; 2018 Dec; 24(8):574-583. PubMed ID: 28732453 [TBL] [Abstract][Full Text] [Related]
19. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529 [TBL] [Abstract][Full Text] [Related]
20. Pazopanib for the treatment of renal cancer. Al-Marrawi MY; Rini B Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]